- Home
- ADPT
as 04-18-2025 1:30pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 1.1B | IPO Year: | 2019 |
| Target Price: | $9.40 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.28 - $9.01 | Next Earning Date: | 05-01-2025 |
| Revenue: | $178,957,000 | Revenue Growth: | 5.10% |
| Revenue Growth (this year): | 21.2% | Revenue Growth (next year): | 22.06% |
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Mar 24 '25 | Sell | $9.00 | 1,698 | $15,282.00 | 1,279,524 | |
| GRIFFIN MICHELLE RENEE | ADPT | Director | Mar 13 '25 | Sell | $7.19 | 36,291 | $260,932.29 | 15,394 | |
| HERSHBERG ROBERT | ADPT | Director | Mar 12 '25 | Sell | $7.59 | 53,000 | $402,270.00 | 69,690 | |
| NEUPERT PETER M | ADPT | Director | Mar 10 '25 | Sell | $7.05 | 10,000 | $70,500.00 | 224,690 | |
| GRIFFIN MICHELLE RENEE | ADPT | Director | Mar 4 '25 | Sell | $7.94 | 15,664 | $124,372.16 | 15,394 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Mar 4 '25 | Sell | $6.99 | 96,656 | $675,219.41 | 1,279,524 | |
| PISKEL KYLE | ADPT | Chief Financial Officer | Mar 4 '25 | Sell | $6.98 | 10,320 | $72,072.21 | 275,974 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Mar 4 '25 | Sell | $7.20 | 219,569 | $1,600,416.95 | 2,850,495 | |
| BOBULSKY SUSAN | ADPT | Chief Commercial Officer, MRD | Mar 4 '25 | Sell | $6.98 | 26,023 | $181,640.54 | 347,238 | |
| LO FRANCIS | ADPT | Chief People Officer | Mar 4 '25 | Sell | $6.99 | 20,875 | $145,845.40 | 332,846 |
Latest Adaptive Biotechnologies Corporation News
ADPT Breaking Stock News: Dive into ADPT Ticker-Specific Updates for Smart Investing
Benzinga
7 days ago
OpenAI And Andreessen Horowitz Lead $43M Round For Cybersecurity Startup Taking On AI Scammers, Deepfakes, And Voice Spoofs
GlobeNewswire
9 days ago
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
MT Newswires
11 days ago
Adaptive Biotechnologies' Mantle Cell Lymphoma Test Receives Expanded Medicare Coverage
GlobeNewswire
11 days ago
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
MT Newswires
a month ago
Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close
MT Newswires
a month ago
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8
Insider Monkey
a month ago
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March
GlobeNewswire
a month ago
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
Compare ADPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.